Last Update: 1969-12-31

Number of Stocks:
Number of New Stocks:

Total Value: $0 Mil
Q/Q Turnover: %

Countries: USA
Details: Top Buys | Top Sales | Top Holdings  Embed:


  • Boeing Achieves Breakthroughs In Fuel And Aerospace Technologies

    Boeing (BA) ended the flight testing of its 787 EcoDemonstrator last Wednesday. The company had, for the last few months, been testing this beauty of an aircraft which involves 25 technologies designed to increase efficiency and reduce noise and emissions. The main motive of such trials, using 787 Dreamliner flight-test article ZA004, was to evaluate advances in software and connectivity, improvements in aerodynamics and flight controls, remote sensors to reduce wiring and “icephobic” wing coatings to mitigate ice accumulation.

    Breakthroughs In Aerospace Technology:


  • Murray Stahl’s Horizon Kinetics Comments on Royal Gold Inc

    An idiosyncratic security with benefits – a diversifier

    Let’s find a contrasting investment to a utility index or a REIT index, which are front and center as bond substitutes or asset allocation building blocks. They are therefore closely governed in valuation and price behavior by the asset flows of index investors and, so, might be particularly vulnerable to a rise in interest rates. Consider, instead, a very distinctive security like Royal Gold, Inc (RGLD). It is categorized in financial securities databases like a gold mining company. Yet it does not do any mining, and on a balance sheet and income statement basis has as little in common with gold mining as Microsoft (MSFT): it has virtually no property, plant, or equipment, it carries no net debt, it has extremely high after-tax cash flow margins—well over 50%. Microsoft’s are roughly 25%. Its financial statements and casually observable economics say that it really does not belong with the gold mining group.


  • US Dollar still rising in the Face of Challenges

    As the year is ending, the US dollar is still showing signs of improvement in the face of various challenges. On Thursday, it was reported that the dollar rose against other major currencies and could continue its advance into 2015. This hike came even after Federal Reserves sent a signal to the public that a rate hike might be on its way soon. Foreign exchange companies like Prime Trade and others are watching closely as the US dollar outperforms its counterparts.

    In Switzerland, the Swiss National Bank tried to limit access to the US dollar by threatening to bring about an interest rate of -0.25% on deposits that are of large proportion held by French citizens living in France. This move made by the Swiss bank was in keeping with their regulations in trying to stay safe in regards to their monetary policies.


  • Murray Stahl’s Horizon Kinetics 3Q 2014 Commentary

    This year’s commentaries review some of the surprising ways in which scientific-seeming or rule-based approaches to investing, which are now the norm and implemented via exchange-traded funds (ETFs) and index-based mutual funds, are foiled in practice by the social science reality of the fluid marketplace. A formulaic approach can work for a while, until a sufficient number of additional investors apply it. Their aggregate actions impact the supply/demand balance, valuations change, and the formula can no longer work. In reviewing some popular building blocks of the asset allocation model of investing, we have, hopefully, demonstrated:

    -That an emerging markets index probably does not contain much in the way of emerging markets exposure, so much as exposure to large, relatively mature companies, many of which are exporters that, economically, are really global companies, not local. That the historical excess returns recorded by emerging markets indexes are probably not a reliable set of figures. That a non-indexed approach, or a different form of index, could better capture the local-economy potential of emerging markets.


  • Express Scripts Knocks Gilead’s Hep C Drug in Favor of AbbVie

    Shares of Gilead Sciences (NASDAQ: GILD) took a hit on Friday, December 19th after Express Scripts (NASDAQ: ESRX) gave AbbVie (NYSE: ABBV) exclusive distribution of their hepatitis C drug, Viekira Pak. The drug received FDA approval on December 19th and is a considered a direct competitor of Gilead’s Harvoni regimen. Express Scripts manages prescription benefits and this decision makes AbbVie the sole distributor of hepatitis C drugs for Express Scripts’ 25 million subscribers. Starting January 1st, Express Script beneficiaries will no longer be covered to purchase Harvoni.

    Express Scripts values affordability for patients, which played a role in their decision to choose AbbVie’s hepatitis C regimen over Gilead’s. Steve Miller, M.D., senior vice president and chief medical officer of Express Scripts, stated, “Express Scripts and AbbVie have a single focus: do what’s right for hepatitis C patients… This agreement marks a fundamental change in how sustainable access and affordability will be delivered to hepatitis C patients.”


  • Examining Ford's Long-Term Prospects

    Ford’s (F) recently reported results that turned out to be quite solid, but all was not well with The Blue Oval. Let us take a look what the company has in store for investors and how does it plan to address the European conundrum.

    The European market


  • Why Qualcomm Looks Like a Good Buy For the Long Run

    Qualcomm (QCOM) has a very wide market for networked mobile device, and it provides almost every known service relating to modern wireless communications. It collects heavy license fees from other companies to make CDMA chips which it pioneers. The company’s chip business is highly profitable and growing.

    The company also supplies the heart of a mobile, its processor. Nokia Lumia 920, a premium Windows phone runs on Qualcomm's processor, Snapdragon dual-core. Further, Qualcomm's dominance in 4G LTE baseband hardware sales has led to the adoption of its Snapdragon S4 processors. Snapdragon processors are one of the best processors in the world and the company continuously remodels them to suit the needs of its users.


  • Ross Stores Will Continue To Grow

    Ross Stores Inc. (ROST) operates as off-price retail apparel and home fashion stores in United States under the brand name of Ross Dress for Less and dds discount. The company offers apparel, accessories, footwear and home fashions with 1,172 stores in 33 states, the District of Columbia and Guam.

    Ross’ first brand Ross Dress for Less stores sells its product at an everyday savings of 20% to 60% off department and specialty store regular prices mostly to middle income households. The other brand dd’s DISCOUTS primarily focuses a more moderate income household at an everyday savings of 20% to 70% off moderate department.


  • Allot Communications Fell 18% in the Past Month Despite Bullish Analyst Ratings

    Allot Communications LTD (NASDAQ: ALLT) has fallen 18% in the past month as a result of President Obama calling for the “strongest possible rules” to protect the open Internet, explicitly banning paid prioritization.

    To put it simply, Obama’s proposal prohibits the blocking of websites, slowing of Internet content, and deals that let companies pay for faster delivery of their content.


  • Pantheon Ventures Reprices Private Placement

  • ProMetic Enters Into Strategic Alliance with GENERIUM Pharmaceuticals

  • Staffing 360 Solutions Announces Above-Market Conversion of $3.3 Million Debt Into Equity

  • Maudore Cease Trade Order Lifted

  • Crown Point Agrees to Revised Terms for US$15 Million Equity Financing, Closes First Tranche and Appoints Two New Board Members

  • Anglo Pacific Group PLC: Portfolio Update

  • AltaGas Ltd. Delivers COD Certificate for Its 16 MW Volcano Creek Hydroelectric Facility

  • FONU2 Announces Social Commerce Strategy

  • ContraFect Receives FDA Approval to Initiate Clinical Trials of CF-301 for MRSA Bloodstream Infections

  • Redhill Provides Operational and Financial Update

  • Exeter Drilling Continues to Encounter Significant Water

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial